Bontril PDM, a brand-name weight loss medication containing phendimetrazine tartrate, was not pulled from the market due to a single safety scandal or FDA recall. Instead, it appears to have been quietly discontinued as a branded product by its manufacturer, Bausch Health (formerly Valeant Pharmaceuticals), likely due to a combination of commercial factors: limited approved use, competition from newer weight loss drugs, and the ongoing availability of cheaper generic versions of the same active ingredient. The FDA’s Orange Book records show a change in the applicant holder status for Bontril PDM, but no formal safety-based withdrawal.
Phendimetrazine tartrate itself remains FDA-approved and available by prescription in generic form. So the drug didn’t disappear. The brand name did.
What Bontril Was Prescribed For
Bontril PDM contained phendimetrazine tartrate at 35 mg per tablet. It was approved as a short-term aid for weight loss in people with a BMI of 30 or higher who hadn’t lost enough weight through diet and exercise alone. “Short-term” meant a few weeks, not months. The drug works as an appetite suppressant, chemically and pharmacologically related to amphetamines.
That narrow window of approved use was a significant limitation. The body develops tolerance to phendimetrazine’s appetite-suppressing effect within just a few weeks, at which point the drug stops working and is supposed to be stopped. As the FDA labeling bluntly notes, “the natural history of obesity is measured in years, whereas the studies cited are restricted to a few weeks duration.” In other words, the drug offered a temporary nudge at best.
Why the Brand Likely Left the Market
Pharmaceutical companies discontinue branded products for business reasons all the time, and Bontril fits a common pattern. The drug was first approved in December 1976. After decades on the market, its patent protections had long expired, and multiple generic versions of phendimetrazine tartrate became available at a fraction of the cost. When generics dominate a market, there’s little financial incentive for a manufacturer to keep producing, marketing, and maintaining regulatory compliance for a branded version.
The weight loss drug landscape also shifted dramatically. Newer medications with longer treatment durations and stronger clinical data, including GLP-1 receptor agonists like semaglutide and tirzepatide, changed what both doctors and patients expected from obesity treatment. A decades-old stimulant approved for only a few weeks of use became increasingly difficult to justify commercially.
Bontril also carried regulatory baggage. As a Schedule III controlled substance with amphetamine-like properties, it required tighter prescribing controls and came with abuse potential that made many providers cautious. None of these factors alone would kill a product, but together they made the brand economically unviable.
Safety Concerns That Shadowed the Drug
While safety issues don’t appear to be the direct reason Bontril was discontinued, phendimetrazine carried a long list of serious risks that limited its appeal. The most alarming: using appetite suppressants in this drug class for longer than three months was associated with a 23-fold increase in the risk of developing pulmonary hypertension, a dangerous condition where blood pressure in the lungs rises to harmful levels. This finding echoed the broader concerns that led to the withdrawal of fenfluramine (part of the infamous “fen-phen” combination) in the late 1990s.
Phendimetrazine was contraindicated in people with a history of heart or blood vessel disease, heart valve problems, uncontrolled high blood pressure, stroke, or pulmonary hypertension. Its side effect profile included chest pain, fast or irregular heartbeat, trouble breathing, swelling of the feet or lower legs, fainting, and numbness or tingling in the limbs. These cardiovascular risks made it a poor fit for many of the patients who needed weight loss treatment most, since obesity often coexists with heart disease and high blood pressure.
The abuse potential was another persistent concern. Reports documented patients increasing their doses far beyond what was recommended. Abruptly stopping the drug after prolonged high-dose use could trigger extreme fatigue and mental depression. Chronic misuse sometimes produced psychosis that was clinically indistinguishable from schizophrenia, along with severe skin problems, marked insomnia, and personality changes.
Generic Phendimetrazine Is Still Available
If your doctor previously prescribed Bontril, the active ingredient hasn’t vanished. Generic phendimetrazine tartrate tablets remain FDA-approved and available by prescription, including both immediate-release tablets and extended-release capsules. A marketing start date of November 2022 for one generic formulation confirms that the drug continues to be actively distributed.
That said, prescribing patterns have shifted. Many weight management specialists now favor newer medications that can be used long-term and have demonstrated cardiovascular benefits rather than risks. If you were taking Bontril and found it helpful, a generic equivalent exists, but it’s worth discussing current options with your provider since the treatment landscape has changed substantially since phendimetrazine’s heyday.
How Bontril Compares to Current Weight Loss Drugs
The contrast between phendimetrazine and modern obesity medications highlights why older stimulant-based appetite suppressants have fallen out of favor. Phendimetrazine was approved for a few weeks of use, produced tolerance quickly, carried serious cardiovascular warnings, and had meaningful abuse potential as a controlled substance. The clinical evidence supporting it was based on short studies that showed modest weight loss beyond what dieting alone achieved.
Current GLP-1 based medications are approved for long-term use, have produced average weight loss of 15% to 20% or more of body weight in clinical trials, and some have demonstrated reduced risk of heart attacks and strokes. That gap in efficacy and safety profile explains why phendimetrazine, while still technically available, has been largely sidelined in clinical practice. The discontinuation of the Bontril brand name simply reflected a market reality that had been building for years.